Health Plan Disenrollment and Mortality After Initiation of Medications for Opioid Use Disorder

What is the association of health plan disenrollment with all-cause mortality and overdose mortality in patients treated with medications for opioid use disorder?In this cohort study of 20 011 patients aged 16 years and older who were treated with buprenorphine or naltrexone for opioid use disorder, health plan disenrollment was associated with a 51% and 56% increase in the hazards of all-cause mortality and overdose mortality, respectively.These findings suggest health plan disenrollment is a risk factor for elevated mortality in patients being treated with medications for opioid use disorder.

Corresponding Author: Anh P. Nguyen, PhD, Institute for Health Research, Kaiser Permanente Colorado, PO Box 378066, Denver, CO 80237-8066 (anh.p.nguyen@kp.org).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.